|
|
|
eMedicine Journal
>
Emergency Medicine
>
Gastrointestinal
Diverticular Disease Synonyms, Key Words, and Related Terms: acute diverticulitis, diverticulosis, lower gastrointestinal bleeding, lower GI bleeding, Meckel iliac diverticulum, congenital diverticula, peridiverticular inflammation, tenesmus, recurrent urinary tract infections, colovesicular fistulas, pneumaturia, feculent vaginal discharge, low-fiber diet, high fat diets, beef diets, colonic segmentation, defects in colonic wall strength |
||||||||||
|
Author Information | Introduction | Clinical | Differentials | Workup | Treatment | Medication | Follow-up | Miscellaneous | Test Questions | Pictures | Bibliography
|
| AUTHOR INFORMATION | Section 1 of 12 |
Authored by A Antoine Kazzi, MD, Chief of Service, Department of Emergency Medicine, Medical Director of the Emergency Unit, American University of Beirut
Coauthored by Ziad N Kazzi, MD, Assistant Professor, Medical Toxicologist, Department of Emergency Medicine, University of Alabama in Birmingham
A Antoine Kazzi, MD, is a member of the following medical societies: American Academy of Emergency Medicine, American Medical Association, California Medical Association, and Society for Academic Emergency Medicine
Edited by Steven A Conrad, MD, PhD, Chief, Department of Emergency Medicine; Chief, Multidisciplinary Critical Care Service, Professor, Department of Emergency and Internal Medicine, Louisiana State University Health Sciences Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Eugene Hardin, MD, FACEP, FAAEM, Chair and Associate Professor, Department of Emergency Medicine, Charles R Drew University of Medicine and Science; Chair, Department of Emergency Medicine, Martin Luther King, Jr/Drew Medical Center; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; and Barry Brenner, MD, PhD, FACEP, Professor of Emergency Medicine, Professor of Internal Medicine, and Professor of Anatomy and Neurobiology, Research Director, Department of Emergency Medicine, University of Arkansas for Medical Sciences
| Author's Email: | A Antoine Kazzi, MD | |
|---|---|---|
| Editor's Email: | Steven A Conrad, MD, PhD |
eMedicine Journal, June 13 2006, VOLUME 7,
Number 6
| INTRODUCTION | Section 2 of 12 |
Background: Diverticular disease is a common disorder, yet it was not recognized as a pathologic entity until the mid-19th century. Diverticulitis and lower gastrointestinal (GI) bleeding secondary to diverticulosis are the main complications of clinical importance to emergency physicians.
Pathophysiology: Diverticular disease may involve any part of the GI tract. Typically acquired, diverticular disease may be congenital, such as Meckel iliac diverticulum (although this is rare). Diverticula are herniations of the mucosa and submucosa or the entire wall thickness through the muscularis, as seen in congenital diverticula. The sigmoid is the most commonly affected segment (95-98%); however, diverticular disease also can involve the descending, ascending, and transverse colon as well as the jejunum, ileum, and duodenum.
Precise etiology of this disease is unknown. High intraluminal pressure and a weak colonic wall at the sites of nutrient vessel penetration into the muscularis may lead to herniation. The condition also may be caused by abnormal colonic motility, defective muscular structure, defects in collagen consistency (ie, increased cross-linking of collagen), and aging.
Diverticulitis is an abscess or peridiverticular inflammation initiated by the rupture of a microscopic mucosal abscess into the mesentery. The infection may progress, fistulize, obstruct, or spontaneously resolve.
Acute diverticulitis results from the inspissation of fecal material in the neck of the diverticulum and resultant bacterial replication. Lower GI bleeding from diverticulosis results from rupture of the small blood vessels that are stretched while coursing over the dome of the diverticula.
Frequency:
Mortality/Morbidity: Mortality and morbidity are related to complications of diverticulosis, which are mainly diverticulitis and lower GI bleeding. These occur in 10-20% of patients with diverticulosis during their lifetime.
Race:
Sex: Male-to-female ratio is equal.
Age:
| CLINICAL | Section 3 of 12 |
History:
Physical:
Causes:
| DIFFERENTIALS | Section 4 of 12 |
Abdominal Trauma, Blunt
Lymphogranuloma Venereum
Syphilis
Tuberculosis
Other Problems to be Considered:
Actinomycosis
Amebiasis
Angiodysplasias
Carcinoma of the colon (particularly distal colon)
Collagen diseases
Fecal impaction
Foreign body granuloma
Gonococcal and nongonococcal proctitis
Infectious colitis
Irritable bowel syndrome
Ischemic colitis
Meckel diverticulitis
Postirradiation proctosigmoiditis
| WORKUP | Section 5 of 12 |
Lab Studies:
Imaging Studies:
Procedures:
| TREATMENT | Section 6 of 12 |
Prehospital Care:
Emergency Department Care:
Consultations: Consult with general surgery if the patient presents with any of the following:
| MEDICATION | Section 7 of 12 |
Goals of pharmacotherapy are to treat the infection and prevent complications.
Drug Category: Antibiotics -- Therapy for diverticulitis must cover all likely pathogens in the clinical setting including anaerobes (eg, bacterids) and gram-negative organisms (eg, Enterobacteriaceae, enterococci). Complicated diverticulitis is commonly treated using a combination of metronidazole or clindamycin with an aminoglycoside or third-generation cephalosporin. More recent regimens commonly used include beta-lactam/beta-lactamase combinations (eg, ampicillin/sulbactam, piperacillin/tazobactam). In more severe cases, imipenem may be used. Milder cases of diverticulitis are treated on an outpatient basis with a PO regimen that includes ciprofloxacin with metronidazole. Recently, rifampin has been used in the treatment of milder cases of acute diverticulitis. Initial studies evaluating the use of mesalazine have shown benefit when used in combination with another antibiotic, such as rifampin, in improving outcome and decreasing the frequency of recurrences.
| Drug Name | Metronidazole (Flagyl) -- Active against various anaerobic bacteria and protozoa. Appears to be absorbed into the cells, and intermediate-metabolized compounds that are formed bind DNA and inhibit protein synthesis, causing cell death. |
|---|---|
| Adult Dose | Load 15 mg/kg IV over 1 h; followed by 7.5 mg/kg PO/IV q6h; not to exceed 4 g/d |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; active organic disease of CNS such as epilepsy; blood dyscrasias or history of cardiac function impairment (because of sodium content); severe hepatic function impairment; lactation or first trimester of pregnancy |
| Interactions | May increase toxicity of anticoagulants, lithium, and phenytoin; cimetidine may increase toxicity of metronidazole; disulfiram reaction may occur with orally ingested ethanol |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy |
| Drug Name | Clindamycin (Cleocin) -- Lincosamide useful as treatment against serious skin and soft tissue infections caused by most staphylococci strains. Also effective against aerobic and anaerobic streptococci, except enterococci. Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at the bacterial ribosome where it preferentially binds to the 50S ribosomal subunit, causing bacterial replication inhibition. |
|---|---|
| Adult Dose | 150-450 PO mg q6h; 300-900 mg IV/IM q6-12h; not to exceed 4800 mg/d |
| Pediatric Dose | 8-20 mg/kg/d PO as hydrochloride and 8-25 mg/kg/d as palmitate divided tid/qid; 20-40 mg/kg/d IV/IM divided tid/qid |
| Contraindications | Documented hypersensitivity; regional enteritis, ulcerative colitis, hepatic impairment, antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
| Drug Name | Ampicillin (Omnipen, Marcillin) -- Interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. |
|---|---|
| Adult Dose | 1-2 g PO qd divided q6h; 2-8 g IV/IM qd divided q4-6h |
| Pediatric Dose | 50 mg/kg IV/IM |
| Contraindications | Documented hypersensitivity; life-threatening reactions to other beta-lactams |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
| Drug Name | Amoxicillin (Amoxil, Polymox, Trimox) -- Used orally when outpatient management is indicated. Improves compliance because of dosing frequency and duration. Interferes with synthesis of cell wall mucopeptide during active replication, resulting in bactericidal activity against susceptible bacteria. |
|---|---|
| Adult Dose | 500 mg PO tid for 6 d |
| Pediatric Dose | 20-50 mg/kg/d PO divided q8h |
| Contraindications | Documented hypersensitivity |
| Interactions | Reduces efficacy of oral contraceptives; aspirin and probenecid increase amoxicillin concentrations; increased risk of bleeding with concomitant oral anticoagulants |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal impairment |
| Drug Name | Ciprofloxacin (Cipro) -- Bactericidal antibiotic that inhibits bacterial DNA synthesis and consequently replication by inhibiting DNA-gyrase in susceptible organisms. Indicated for pseudomonal infections and those from multidrug-resistant gram-negative organisms. |
|---|---|
| Adult Dose | 250-500 mg PO q12h for 5-7 d; 200 mg IV q12h |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; do not administer to pediatric patients, since quinolones may cause arthropathy in children because of cartilage hardening |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; ciprofloxacin reduces therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations May increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Cephalexin (Keflex, Biocef) -- Used orally when outpatient management is indicated. First-generation cephalosporin that inhibits bacterial replication by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls. Primarily active against skin flora; typically used for skin structure coverage and as prophylaxis in minor procedures. |
|---|---|
| Adult Dose | 250-500 mg PO q6h |
| Pediatric Dose | 25-50 mg/kg/d PO divided q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity increases with aminoglycosides, furosemide, colistin, ethacrynic acid, and vancomycin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal impairment |
| Drug Name | Imipenem and cilastatin (Primaxin) -- Used for treatment of multiple-organism infections in which other agents do not have wide-spectrum coverage or are contraindicated because of potential toxicity. |
|---|---|
| Adult Dose | 250-500 mg IV q6h; in severe infections, may increase to 1g q6h; IM q12h; not to exceed total daily dose of 1500 mg |
| Pediatric Dose | 10-15 mg/kg IV q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with cyclosporine may increase CNS adverse effects of both agents; coadministration with ganciclovir may result in generalized seizures |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Adjust dose in renal insufficiency; avoid use in children <12 y |
| Drug Name | Cefoxitin (Mefoxin) -- Second-generation cephalosporin indicated for management of infections caused by susceptible gram-positive cocci and gram-negative rods. Many infections are caused by gram-negative bacteria, are resistant to some cephalosporins and penicillins, and respond to cefoxitin. |
|---|---|
| Adult Dose | 1-2 g IV/IM q6-8h or q4h if infection is severe |
| Pediatric Dose | 80-160 mg/kg/d IV divided q4-6h; higher doses for severe or serious infections; not to exceed 12 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effects of cefoxitin; coadministration with aminoglycosides or furosemide may increase nephrotoxicity (closely monitor renal function) |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged use or repeated treatment; caution in patients with previously diagnosed colitis |
| Drug Name | Ticarcillin and clavulanate potassium (Timentin) -- Inhibits biosynthesis of cell wall mucopeptide and is effective during active replication. Antipseudomonal penicillin and beta-lactamase inhibitor that provides coverage against most gram-positive and gram-negative bacteria and most anaerobes. |
|---|---|
| Adult Dose | INF 1 vial containing ticarcillin 3 g IV and clavulanate 0.1 g IV q4-6h over 30 min |
| Pediatric Dose | 75 mg/kg IV q6h |
| Contraindications | Documented hypersensitivity; do not treat severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis with oral penicillin during acute stage |
| Interactions | Tetracyclines may decrease effects of ticarcillin; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; effects when administered concurrently with aminoglycosides are synergistic; probenecid may increase penicillin levels |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Perform CBC counts prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients diagnosed with hepatic insufficiencies; perform urinalysis and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions |
| Drug Name | Ampicillin-sulbactam sodium (Unasyn) -- Combination antimicrobial agent that uses beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. |
|---|---|
| Adult Dose | 1 g ampicillin/0.5 g sulbactam IV or 2 g ampicillin/1 g sulbactam q6h; not to exceed 4 g of sulbactam/d |
| Pediatric Dose | <12 years: 100-200 mg ampicillin/kg/d (150-300 mg Unasyn) IV divided q6h >12 years: Administer as in adults; not to exceed 4 g/d sulbactam or 8 g/d ampicillin |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
| Drug Name | Rifampin (Rimactane, Rifadin IV, Rifadin) -- Inhibits RNA synthesis in bacteria by binding to beta subunit of DNA-dependent RNA polymerase, which, in turn, blocks RNA transcription. |
|---|---|
| Adult Dose | 10 mg/kg/d PO/IV; not to exceed 600 mg/d |
| Pediatric Dose | 10-20 mg/kg PO/IV; not to exceed 600 mg/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Induces microsomal enzymes, which may decrease effects of acetaminophen, oral anticoagulants, barbiturates, benzodiazepines, beta-blockers, chloramphenicol, oral contraceptives, corticosteroids, mexiletine, cyclosporine, digitoxin, disopyramide, estrogens, hydantoins, methadone, clofibrate, quinidine, dapsone, tazobactam, sulfonylureas, theophyllines, tocainide, and digoxin; blood pressure may increase with coadministration of enalapril; coadministration with isoniazid or pyrazinamide may result in higher rate of hepatotoxicity than with either agent alone (discontinue 1 or both agents if alterations in LFTs occur) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Obtain CBCs and baseline clinical chemistries prior to and throughout therapy; in liver disease, weigh benefits against risk of further liver damage; interruption of therapy and high-dose intermittent therapy are associated with thrombocytopenia that is reversible if therapy is discontinued as soon as purpura occurs; if treatment is continued or resumed after appearance of purpura, cerebral hemorrhage or death may occur |
| Drug Name | Piperacillin and tazobactam sodium (Zosyn) -- Antipseudomonal penicillin plus beta-lactamase inhibitor. Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active multiplication. |
|---|---|
| Adult Dose | 3/0.375 g (piperacillin 3 g and tazobactam 0.375 g) IV q6h |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis should not be treated with an oral penicillin during the acute stage |
| Interactions | Tetracyclines may decrease effects of piperacillin; high concentrations of piperacillin may physically inactivate aminoglycosides if administered in same IV line; when administered concurrently with aminoglycosides, effects are synergistic; probenecid may increase penicillin levels; high-dose parenteral penicillins may result in increased risk of bleeding |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Perform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT levels during therapy; caution in patients with hepatic insufficiencies; perform urinalysis, and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions |
| FOLLOW-UP | Section 8 of 12 |
Further Inpatient Care:
Further Outpatient Care:
Transfer:
Deterrence/Prevention:
Complications:
Prognosis:
Patient Education:
| MISCELLANEOUS | Section 9 of 12 |
Medical/Legal Pitfalls:
Special Concerns:
| TEST QUESTIONS | Section 10 of 12 |
CME Question 1: Which of the following measures should not be taken in a patient with suspected acute diverticulitis?
A: Placement of a nasogastric tube
B: Barium contrast enema
C: CT scan of the abdomen and pelvis
D: Giving the patient nothing by mouth
E: Starting empirical antibiotic treatment
The correct answer is B: A barium contrast enema is contraindicated in acute diverticulitis. The concern is a potential barium leak into the peritoneum in the instance of a perforation. The use of water-soluble contrasts is safe. All of the other procedures are indicated.
CME Question 2: Which of the following is not a symptom of acute diverticulitis?
A: Lower abdominal pain
B: Change in bowel habits
C: Nausea or vomiting
D: Painless lower gastrointestinal bleeding
E: Fever
The correct answer is D: Rectal bleeding is rare in acute diverticulitis. Diverticulitis is never painless. Conversely, lower gastrointestinal bleeding secondary to diverticulosis is typically painless. All other symptoms are common features in acute diverticulitis.
Pearl Question 1 (T/F): Those older than 45 years are most affected by diverticular disease.
The correct answer is True: Persons older than 45 years mostly are affected by diverticular disease. One third of the population older than 45 years and two thirds of those older than 85 years have diverticular disease. It can affect younger age groups; when it does, it may have a more complicated course.
Pearl Question 2 (T/F): Colovesicular diverticula are the most common type of fistulas that form secondary to recurrent episodes of diverticulitis.
The correct answer is True: Colovesicular diverticula are the most common, followed by colovaginal fistulas. Any adjacent structure can be involved.
Pearl Question 3 (T/F): Leukocytosis is a reliable indicator of acute diverticulitis.
The correct answer is False: Leukocytosis is initially absent at presentation in the majority of patients with proven acute diverticulitis. This is particularly true in elderly and immunocompromised patients.
Pearl Question 4 (T/F): The sigmoid colon is the bowel segment most commonly affected by diverticular disease.
The correct answer is True: The sigmoid colon is affected most commonly, although any bowel segment can be involved.
| PICTURES | Section 11 of 12 |
| Caption: Picture 1. Diverticulitis acute fatty stranding. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: CT | |
| Caption: Picture 2. "Thumbprinting" (seen in left mid quadrant) on a plain abdominal radiograph. | |
View Full Size Image | |
eMedicine Zoom View (Interactive!) | |
| Picture Type: X-RAY | |
| Caption: Picture 3. "Thumbprinting" (seen in left mid quadrant) on a plain abdominal radiograph (close-up image). | |
View Full Size Image | |
eMedicine Zoom View (Interactive!) | |
| Picture Type: X-RAY | |
| Caption: Picture 4. Thickening of the bowel wall in the descending colon due to bowel edema can be seen in the left lower quadrant on this plain abdominal radiograph. Note the narrowed colonic lumen. Note the CT scan images in this article are from the same 62-year-old patient with diverticulitis. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: X-RAY | |
| Caption: Picture 5. Thickening of the bowel wall in the descending colon due to bowel edema can be seen in the left lower quadrant on this plain abdominal radiograph. Note the narrowed colonic lumen. Note the CT scan images in this article are from the same 62-year-old patient with diverticulitis. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: X-RAY | |
| Caption: Picture 6. Thickening of the bowel wall in the descending colon due to bowel edema can be seen in the left lower quadrant on this CT scan. Note the narrowed colonic lumen (contrast in the lumen is white). Note the hypodense (dark) spot in the bottom right of the edematous colonic wall; this spot is an abscess that is forming within the bowel wall in a 62-year-old patient with diverticulitis. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: CT | |
| Caption: Picture 7. Sigmoid diverticulitis in a 50-year-old male patient with history of diverticulosis and left lower abdominal pain and tenderness. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: CT | |
| Caption: Picture 8. Thickening of the bowel wall in the descending colon due to bowel edema can be seen in the left lower quadrant on this CT scan. Note the narrowed colonic lumen (contrast in the lumen is white). Note the hypodense (dark) spot in the bottom right of the edematous colonic wall; this spot is an abscess that is forming within the bowel wall in a 62-year-old patient with diverticulitis. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: CT | |
| Caption: Picture 9. Sigmoid diverticulitis in a 50-year-old male patient with history of diverticulosis and left lower abdominal pain and tenderness. Images 9-12 are sections from the same patient. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: CT | |
| Caption: Picture 10. Sigmoid diverticulitis in a 50-year-old male patient with history of diverticulosis and left lower abdominal pain and tenderness. Images 9 and 11-12 are sections from the same patient. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: CT | |
| Caption: Picture 11. Phlegmon. Sigmoid diverticulitis in a 50-year-old male patient with history of diverticulosis and left lower abdominal pain and tenderness. Images 11-12 are consecutive sections of the patient in Image 9-10 showing a phlegmon. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: CT | |
| Caption: Picture 12. Phlegmon. Sigmoid diverticulitis in a 50-year-old male patient with history of diverticulosis and left lower abdominal pain and tenderness. Images 9-11 are sections from the same patient. | |
![]() | View Full Size Image |
eMedicine Zoom View (Interactive!) | |
| Picture Type: CT | |
| BIBLIOGRAPHY | Section 12 of 12 |
| NOTE: |
|---|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |
| eMedicine Journals > Emergency Medicine > Gastrointestinal > Diverticular Disease |
| Please email us with any comments you have on our new chapter format. |
|
Author Information | Introduction | Clinical | Differentials | Workup | Treatment | Medication | Follow-up | Miscellaneous | Test Questions | Pictures | Bibliography
|
|